STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Dale B. Schenk, et al.
Application No./Patent No.: 10/789,273 Filed/Issue Date: February 27, 2004
Titled: Humanized Antibodies that Recognize Beta Amyloid Peptide
Janssen Alzheimer Immunotherapy; , a Corporation;
(Name of Assignees) (Type of Assignee: corporation, partnership, university, government agency, etc.)
states that it is:
1. the assignee of the entire right, title, and interest in;
 an assignee of less than the entire right, title, and interest in the patent application identified above: the extent of its ownership interest is 50%. Wyeth LLC and Janssen Abzheimer Immunotherapy are each an assignee of a joint right, title, and interest in the patent application identified above. There are no other assignees.
3. the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors)
the patent application/patent identified above, by virtue of either:
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy there
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:
Common Guriq Basi, Jose Saldanha, and Ted To: Elan Pharmaceuticals, Inc. Yednock
The document was recorded in the United States Patent and Trademark Office at
Reel 023385 , Frame 0779 , or for which a copy thereof is attached.
2. From: Elan Pharmaceuticals, Inc. To: Neuralab Limited and Wyeth
The document was recorded in the United States Patent and Trademark Office at
Reel 023386 , Frame 0028 , or for which a copy thereof is attached.
3. From: Neuralab Limited To: Elan Pharma International Limited and Wyeth
The document was recorded in the United States Patent and Trademark Office at
Reel <u>023386</u> , Frame <u>0053</u> , or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet (s).
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. <u>See</u> MPEP 302.08]
The undersigned (whose title is supplied below, is authorized to jet on behalf of Janssen Alzheimer Immunotherapy, an assignee. 10/13/20/3 Signature United States United States
Rosemarie L. Celli, Registration No. 42,397 Attorney of Record Typed or Printed Name Title
.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

Supplemental Sheet to Statement Under 3.73(b)
Attorney Docket No.: 057436-392211
Application No.: 10/789,273
Filing Date: February 27, 2004

Additional documents in the chain of title:

4.	From:	Elan Pharma International Limited 10. Chinagda Limited and VVVcti
		The document was recorded in the United States Patent and Trademark Office at
		Reel: 023386 Frame: 0058; or for which a copy thereof is attached.
5	From:	Crimagua Limited To: Janssen Alzheimer Immunotherapy and Wyeth
٥.		The document was recorded in the United States Patent and Trademark Office at
		Reel: 023386 Frame: 0070 ; or for which a copy thereof is attached.
6.	From:	Change of Name - Wyeth _ To: _ Wyeth LLC
		The document was recorded in the United States Patent and Trademark Office at
		Reel: 024160 Frame: 0365 : or for which a copy thereof is attached.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Dale B. Schenk, et al.				
Application No./Patent No.: 10/789,273 Filed/Issue Date: February 27, 2004				
Titled: Humanized Antibodies that Recognize Beta Amyloid Peptide				
Wyeth LLC; , a Limited Liability Company;				
(Name of Assignees) (Type of Assignee: corporation, partnership, university, government agency, etc.)				
states that it is:				
1.				
 an assignee of less than the entire right, title, and interest in the patent application identified above; the extent of its ownership interest is <u>50%</u>. Wyeth LLC and Janssen Alzheimer immunotherapy are each an assignee of a joint right, title, and interest in the patent application identified above. There are no other assignees. 				
3.				
the patent application/patent identified above, by virtue of either:				
A. An assignment from the Inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.				
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:				
A chain of time from the investings, or the patent application patent is consistent according to the second of the description of the patent application patent is consistent according to the patent application patent application patent is consistent according to the patent application patent according to the patent acco				
The document was recorded in the United States Patent and Trademark Office at				
Reel _023385, Frame _0779, or for which a copy thereof is attached.				
2. From: Elan Pharmaceuticals, Inc. To: Neuralab Limited and Wyeth				
The document was recorded in the United States Patent and Trademark Office at				
Reel 023386 , Frame 0028 , or for which a copy thereof is attached.				
3. From: Neuralab Limited To: Elan Pharma International Limited and Wyeth				
The document was recorded in the United States Patent and Trademark Office at				
Reel 023386 , Frame 0053 , or for which a copy thereof is attached.				
Additional documents in the chain of title are listed on a supplemental sheet (s).				
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.				
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]				
The undersigned (whose title is supplied below, is authorized to act on behalf of Janssen Alzheimer Immunotherapy, an assignee.				
Signature '/ Date				
Rosemarie L. Celli, Registration No. 42,397 Attorney of Record Typed or Printed Name Title				
Typed of Filition Hamo				

Supplemental Sheet to Statement Under 3.73(b)
Attorney Docket No.: 057436-392211
Application No.: 10/789,273
Filing Date: February 27, 2004

Additional documents in the chain of title:

4.	From:	Elan Pharma International Limited 10. Chinagda Limited and VVVcti
		The document was recorded in the United States Patent and Trademark Office at
		Reel: 023386 Frame: 0058; or for which a copy thereof is attached.
5	From:	Crimagua Limited To: Janssen Alzheimer Immunotherapy and Wyeth
٥.		The document was recorded in the United States Patent and Trademark Office at
		Reel: 023386 Frame: 0070 ; or for which a copy thereof is attached.
6.	From:	Change of Name - Wyeth _ To: _ Wyeth LLC
		The document was recorded in the United States Patent and Trademark Office at
		Reel: 024160 Frame: 0365 : or for which a copy thereof is attached.